Skip to main content

Satranidazole and My Pharmaceutical Research Odyssey: A Success Story

  • 462 Accesses


The start of my nearly 40 yearlong pharmaceutical research odyssey almost coincides with the beginning of my association with Hindustan Ciba-Geigy Limited, Research Centre, Goregaon, Bombay (now Mumbai), and satranidazole. Satranidazole, an excellent and relatively superior molecule, is the first and the only antiamoebic drug that has been discovered, developed and marketed from India. In future, it may find therapeutic applications for many more indications. It is a product of long-drawn, very expensive and intense scientific and technological efforts, often marred with uncertainties and serendipity, of the dedicated scientists and technicians. Satranidazole had to survive spates of several squabbles but, in the end, has emerged as a champion and seen the light of day. Satranidazole will definitely go a long way to improve and invigorate the quality of human life. Nonetheless, for the new and budding drug researchers, the success story of satranidazole, full of different hues and shades of human complexities, will be a source of distinctive inspiration and has several important lessons to offer.


  • Amoebiasis
  • Antiamoebic drugs
  • Ciba-Geigy
  • Entamoeba cricetti
  • Entamoeba histolytica
  • Entamoeba muris
  • Experimental models
  • Luminal
  • Satranidazole

This is a preview of subscription content, access via your institution.

Buying options

USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-981-13-1577-0_1
  • Chapter length: 10 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
USD   149.00
Price excludes VAT (USA)
  • ISBN: 978-981-13-1577-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   199.99
Price excludes VAT (USA)
Fig. 1.1
Fig. 1.2
Fig. 1.3
Fig. 1.4
Fig. 1.5
Fig. 1.6


  • CIBA to mark 25 years here with program (1962) The summit herald and summit record. May 24, 1962, Summit N. J

    Google Scholar 

  • Nagarajan K, Arya VP, George T, Sudarsanam V, Shah RK, Goud N, Shenoy SJ, Kulkarni VS, Rao MK (1982) Nitroimidazole part 4.1-[methyl-5-nitroimidazolyl(2)]-2-oxo-3-sulphonyl (carbamoyl-thicarbamoyl) tetrahydroimidzoles. Ind. J Chemother 21B:928–940

    CAS  Google Scholar 

  • Singh PP, Sharma VP (2014) Water and Health. pp i–xxiii + 404, Springer India. ISBN: 978-81-322-1028-3 (Print) 978-81-322-1029-0 (Online);

    Google Scholar 

  • Singh PP, Tendulkar JS, Nagarajan K (1985) Amoebicidal activity of CG-10213 GO and other nitroimidazoles against axenically grown Entamoeba histolytica. Ind J Parasit 9:99–100

    CAS  Google Scholar 

  • Singh PP, Srivastava VB, Talwalkar S (1987) Natural Entamoeba muris infection in rats: a new model for screening potential luminal amoebicides. Ind J Parasit 11:15–20

    CAS  Google Scholar 

  • Subrahmanyam D, Radhakrishna V (1985) Symposium of the proceedings of the symposium on recent advances in protozoan diseases

    Google Scholar 

Download references


I thank Dr. K. Nagarajan for the encouragement and generously providing some pictures and documents of archival importance related to satranidazole.

Author information

Authors and Affiliations


Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Singh, P.P. (2018). Satranidazole and My Pharmaceutical Research Odyssey: A Success Story. In: Singh, P. (eds) Infectious Diseases and Your Health. Springer, Singapore.

Download citation